Affimed GmbH
Records under this name other than the patents Affimed GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Showing 1 to 2 of 2 · Back to Affimed GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,701,750 | Anti-CD16 binding molecules Term ended Term ended May 26, 2026 · From the USPTO record | Term ended | Term ended May 26, 2026 | From the USPTO record |
| US 9,226,962 | Human CD3-specific antibody with immunosuppressive properties Lapsed on the fee record Ended Jan 5, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2024 | From the USPTO record |